Primary tumors of the heart

Current Opinion in Cardiology

Volumn 31, Issue 6, 2016, Pages 593-598

  Lestuzzi, Chiara ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Cardiac sarcomas; Cardiac tumors; Cardio oncology; Heart tumors

Indexed keywords

ANGIOSARCOMA; CARDIAC SURGEON; DIFFERENTIAL DIAGNOSIS; EVENT FREE SURVIVAL; FIBROELASTOMA; HEART MYXOMA; HEART SARCOMA; HEART TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SURVIVAL; TUMOR CLASSIFICATION; SARCOMA; VASCULAR TUMOR;

DIAGNOSIS, DIFFERENTIAL; HEART NEOPLASMS; HUMANS; PROGNOSIS; SARCOMA; VASCULAR NEOPLASMS;

EID: 84988643378     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000335     Document Type: Review

References (57)

1. Travis WD, Brambilla E, Burke AP, et al., editors. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon, France: International Agency for Research on Cancer; 2015. Detailed updated classification of the cardiac tumors. Mostly relevant for pathologists.
2. Burke A, Tavora F. The 2015 WHO classification of tumors of the heart and pericardium. J Thorac Oncol 2015; 11:441-452.
3. Fletcher CDM, Chibon F, Mertens F. Undifferentiated/unclassified sarcomas. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. Lyon, France: International Agency for Research on Cancer; 2013. pp. 236-238.
4. Burke AP, Yi ES. Pulmonary artery intimal sarcoma. In: Travis WD, Brambilla E, Burke AP, et al., editors. WHO classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon, France: International Agency for Research on Cancer; 2015128-129.
5. Bode-Lesniewska B, Debiec-Rychter M. Intimal sarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. Lyon, France: International Agency for Research on Cancer; 2013. pp. 232-233.
6. Sebenik M, Ricci A Jr, DiPasquale B, et al. Undifferentiated intimal sarcoma of large systemic blood vessels: report of 14 cases with immunohistochemical profile and review of the literature. Am J Surg Pathol 2005; 29:1184-1193.
7. Neuville A, Collin F, Bruneval P, et al. Intimal sarcoma is the most frequent primary cardiac sarcoma: clinicopathologic and molecular retrospective analysisof 100 primary cardiac sarcomas. Am J Surg Pathol 2014; 38:461-469.
8. Maleszewski JJ, Tavora F, Burke AP. Do 'intimal' sarcomas of the heart exist? Am J Surg Pathol 2014; 38:1158-1159.
9. Geller RL, Hookim K, Sullivan HC, et al. Cytologic features of angiosarcoma: a review of 26 cases diagnosed on FNA. Cancer Cytopathol 2016. [Epub ahead of print]
10. Ray-Coquard I, Montesco MC, Coindre JM, et al. Conticanet group. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. Ann Oncol 2012; 23:2442-2449.
11. Gurzu S, Ciortea D, Munteanu T, et al. Mesenchymal-to-endothelial transition in Kaposi sarcoma: a histogenetic hypothesis based on a case series and literature review. PLoS One 2013; 8:e71530.
12. Demicco EG, Harms PW, Patel RM, et al. Extensive survey of STAT6 expression in a large series of mesenchymal tumors. Am J Clin Pathol 2015; 143:672-682.
13. Demicco EG, Wani K, Fox PS, et al. Histologic variability in solitary fibrous tumors reflects angiogenic and growth factor signaling pathway alterations. Hum Pathol 2015; 46:1015-1026
14. Coindre JM, Hostein I, Maire G, et al. Inflammatory malignant fibrous histiocytomas and dedifferentiated liposarcomas: histological review, genomic profile, and MDM2 and CDK4 status favour a single entity. J Pathol 2004; 203:822-830.
15. Lan J, Huang B, Liu R, et al. Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors. Int J Clin Exp Pathol 2015; 8:12621-12633. A new tool in the study of angiosarcomas.
16. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997; 15:350-362.
17. Tanaka K, Hasegawa T, Nojima T, et al. Prospective evaluation of Ki-67 system in histological grading of soft tissue sarcomas in the Japan Clinical Oncology Group Study JCOG0304. World J Surg Oncol 2016; 14:110.
18. Butany J, Nair V, Naseemuddin A, et al. Cardiac tumours: diagnosis and management [review]. Lancet Oncol 2005; 6:219-228.
19. Hudzik B, Miszalski-Jamka K, Glowacki J, et al. Malignant tumors of the heart. Cancer Epidemiol 2015; 39:665-672.
20. Tamin SS, Maleszewski JJ, Scott CG, et al. Prognostic and bioepidemiologic implications of papillary fibroelastomas. J Am Coll Cardiol 2015; 65:2420-2429.
21. Fleischmann KE, Schiller NB. Papillary fibroelastoma: move over myxoma. J Am Coll Cardiol 2015; 65:2430-2432.
22. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab 2001; 86:4041-4046.
23. Maleszewski JJ, Larsen BT, Kip NS, et al. PRKAR1A in the development of cardiac myxoma: a study of 110 cases including isolated and syndromic tumors. Am J Surg Pathol 2014; 38:1079-1087.
24. Hillenbrand T, Menge F, Hohenberger P, Kasper B. Primary and secondary angiosarcomas: a comparative single-center analysis. Clin Sarcoma Res 2015; 5:14.
25. Sharma A, DeValeria PA, Scherber RM, et al. Angiosarcoma causing cardiac constriction late after radiation therapy for breast carcinoma. Tex Heart Inst J 2016; 43:81-83.
26. Calvete O, Martinez P, Garcia-Pavia P, et al. A mutation in the POT1 gene is responsible for cardiac angiosarcoma in TP53-negative Li-Fraumeni-like families. Nat Commun 2015; 6:8383.
27. Murali R, Chandramohan R, Mö ller I, et al. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget 2015; 6:36041-36052.
28. Kupsky DF, Newman DB, Kumar G, et al. Echocardiographic features of cardiac angiosarcomas: the Mayo clinic experience (1976-2013). Echocardiography 2016; 33:186-192.
29. Porter TR, Abdelmoneim S, Belcik JT, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography. J Am Soc Echocardiogr 2014; 27:797-810.
30. Saric M, Armour AC, Arnaout MS, et al. Guidelines for the use of echocardiography in the evaluation of a cardiac source of embolism. J Am Soc Echocardiogr 2016; 29:1
31. Uenishi EK, Caldas MA, Tsutsui JM, et al. Evaluation of cardiac masses by realtimeperfusion imaging echocardiography. Cardiovasc Ultrasound 2015; 13:23.
32. Hong YJ, Hur J, Kim YJ, et al. The usefulness of delayed contrast-enhanced cardiovascular magnetic resonance imaging in differentiating cardiac tumors from thrombi in stroke patients. Int J Cardiovasc Imaging 2011; 27 (Suppl 1): 89-95.
33. Pazos-Ló pez P, Pozo E, Siqueira ME, et al. Value of CMR for the differential diagnosis of cardiac masses. JACC Cardiovasc Imaging 2014; 7:896-905.
34. Patel R, Lim RP, Saric M, et al. Diagnostic performance of cardiac magnetic resonance imaging and echocardiography in evaluation of cardiac and paracardiac masses. Am J Cardiol 2016; 117:135-140.
35. Rahbar K, Seifarth H, Schä fers M, et al. Differentiation ofmalignant and benign cardiac tumors using 18F-FDG PET/CT. J Nucl Med 2012; 53:856-863.
36. Benz MR, Dry SM, Eilber FC, et al. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med 2010; 51:1174-1181.
37. Manabe O, Yoshinaga K, Ohira H, et al. The effects of 18-h fasting with lowcarbohydrate diet preparation on suppressed physiological myocardial (18)Ffluorodeoxyglucose (FDG) uptake and possible minimal effects of unfractionated heparin use in patients with suspected cardiac involvement sarcoidosis. J Nucl Cardiol 2016; 23:244-252.
38. Samanidis G, Perreas K, Kalogris P, et al. Surgical treatment of primary intracardiac myxoma: 19 years of experience. Interact Cardiovasc Thorac Surg 2011; 13:597-600.
39. Siminelakis S, Kakourou A, Batistatou A, et al. Thirteen years follow-up of heart myxoma operated patients: what is the appropriate surgical technique? J Thorac Dis 2014; 6 (Suppl 1):S32-S38.
40. Aval ZA, Ghaderi H, Tatari H, et al. Surgical treatment of primary intracardiac myxoma: 20-year experience in 'Shahid Modarres Hospital'-a tertiary university hospital-Tehran, Iran. Scientific World J 2015; 2015:303629.
41. Abu Saleh WK, Al Jabbari O, Ramlawi B, Reardon MJ. Cardiac papillary fibroelastoma: single-institution experience with 14 surgical patients. Tex Heart Inst J 2016; 43:148-151.
42. Oh SJ, Yeom SY, Kim KH. Clinical implication of surgical resection for the rare cardiac tumors involving heart and great vessels. J Korean Med Sci 2013; 28:717-724.
43. Habertheuer A, Laufer G, Wiedemann D, et al. Primary cardiac tumors on the verge of oblivion: a European experience over 15 years. J Cardiothorac Surg 2015; 10:56.
44. Vaporciyan A, Reardon MJ. Right heart sarcomas. Methodist Debakey Cardiovasc J 2010; 6:44-48.
45. Ramlawi B, Al-Jabbari O, Blau LN, et al. Autotransplantation for the resection of complex left heart tumors. Ann Thorac Surg 2014; 98:863-868. This article clearly illustrated the surgical problems in treating left atrial tumors, and how to solve them.
46. Kim MP, Correa AM, Blackmon S, et al. Outcomes after right-side heart sarcoma resection. Ann Thorac Surg 2011; 91:770-776.
47. Isambert N, Ray-Coquard I, Italiano A, et al. Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group. Eur J Cancer 2014; 50:128-136. This multicenter study reports the outcome of a large number of cardiac sarcomas and gives information on the prognosis according to histology and different treatments.
48. Ramlawi B, Leja MJ, Abu Saleh WK, et al. Surgical treatment of primary cardiac sarcomas: review of a single-institution experience. Ann Thorac Surg 2016; 101:698-702. The experience of one of the most experienced heart tumor boards.
49. Saraiva J, Antunes PE, Carvalho L, Antunes MJ. Primary malignant cardiac tumors: surgical results. Rev Port Cardiol 2016; 35: 199-204.
50. Le Cesne A, Ouali M, Leahy MG, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol 2014; 25:2425-2432.
51. Oxenberg J, Khushalani NI, Salerno KE, et al. Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: determining tumor behavior prior to surgical resection. J Surg Oncol 2015; 111: 829-833.
52. Frith AE, Hirbe AC, Van Tine BA. Novel pathways and molecular targets for the treatment of sarcoma. Curr Oncol Rep 2013; 15: 378-385.
53. Liebner DA. The indications and efficacy of conventional chemotherapy in primary and recurrent sarcoma. J Surg Oncol 2015; 111:622-631.
54. van der Graaf WT, Blay JY, Chawla SP, et al. EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879-1886.
55. Harwood JL, Alexander JH, Mayerson JL, Scharschmidt TJ. Targeted chemotherapy in bone and soft-tissue sarcoma. Orthop Clin North Am 2015; 46:587-608.
56. Lestuzzi C, De Paoli A, Baresic T, et al. Malignant cardiac tumors: diagnosis and treatment. Future Cardiol 2015; 11:485-500.
57. Fotouhi Ghiam A, Dawson LA, Abuzeid W, et al. Role of palliative radiotherapy in the management of mural cardiac metastases: who, when and how to treat? A case series of 10 patients. Cancer Med 2016; 5: 989-996.